comprehensive -WSS

comprehensive

author：fashion 2025-09-06 02:04:29 - browse：775

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Decaf coffee targeted by food safety group under obscure FDA rule

explore

WSS

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Why some fertility treatments produce more boy babies

FDA's naming rule on biosimilars has undermined competition

Protect nursing home residents from future pandemics

The world needs the new pandemic treaty

Pharma’s losing bet in New Jersey

hotspot

comprehensive

entertainment

At least 13 dead in Texas as scorching temps continue

Study says nonprofit hospitals fall short in charity care spending

After affirmative action ruling, medical educators look to 'holistic review'

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

The cancer drug shortage isn’t new — and neither are the solutions

Protect nursing home residents from future pandemics

Anesthesiologist group: stop taking Ozempic before surgery

Oprah kicked off a national conversation on obesity. Let's have it

Jerome Adams on the need for new antivirals for Covid

Vertex Pharmaceuticals may move headquarters in Boston

explore

Merck drug for rare lung condition set for approval in U.S.

Oprah kicked off a national conversation on obesity. Let's have it

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Hospitals need to get ahead of regulations on climate change

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Beyond aggravation: Constipation is an American epidemic

leisure time

hotspot

explore

Wikipedia